Lixte Biotechnology(LIXT)

Focus: Lixte Biotechnology is a public-stage oncology-focused company developing small molecule diagnostics and therapeutics from Boca Raton, Florida. The company operates at an early clinical stage with minimal commercial infrastructure.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Lixte Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Lixte Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LB-100 for Injection

Tumors

Phase 1

Clinical Trials (1)

NCT01837667Phase I Study of LB-100 With Docetaxel in Solid Tumors

Phase 1

Help build intelligence for Lixte Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in early-stage oncology focused on novel mechanism (LB-100) with potential to shape company trajectory
Public company status provides liquidity optionality and regulatory scrutiny that can accelerate learning
Lean team structure suggests high impact-per-hire and broad responsibility across functions

Watch Out For

Severe cash constraint: $1M cash (FY2025) against $3.6M annual losses indicates runway risk of <4 months without additional capital
No active hiring (0 open roles) and minimal R&D spending ($726K) suggest company is in survival/capital-raising mode rather than growth mode
Pre-revenue status with only Phase 1/2 programs means 7-10+ years to potential commercialization; significant dilution risk for equity holders

Generated by Claude from Lixte Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LB-100

Myelodysplastic Syndromes

Phase 1/2

Clinical Trials (1)

NCT03886662A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$726K19%

Net Income

-$4M

Cash

$1M

Source: SEC 10-K Filing